TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16449030
Drug: Cumulative dosages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dosages and duration of use of diuretics, NMB, vancomycin, and overlap of diuretics with NMB, aminoglycosides, and vancomycin
Study: 4018467
Drug: Lidocaine (L)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (L) - bolus of 1 mg/kg followed by an infusion of 10 mg/min for 20 minutes and thereafter of 1.5 mg/min
Study: 4018467
Drug: Amiodarone (A)
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone (A) - bolus of 5 mg/kg and an eventual repeat dose of 150 mg followed by an infusion of 1.8 g/24 h
Study: 20485707
Drug: Lidocaine (L)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (L)
Study: 26749407
Drug: Ranolazine 1000mg
Normalized name: RANOLAZINE 1000MG TAB,SA
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 1000mg twice daily added to glimepiride
Study: 26749407
Drug: Ranolazine 1000mg
Normalized name: RANOLAZINE 1000MG TAB,SA
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 1000mg twice daily added to metformin
Study: 23025057
Drug: 24-week peginterferon
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-week peginterferon alpha-2a (180 microg/week) plus ribavirin therapy (group A)
Study: 28436395
Drug: Intranasal 200
Normalized name: Influenza, live, trivalent, intranasal 2009-2010 spray [FluMist]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 200 mg GSH
Study: 28436395
Drug: Intranasal 100
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 100 mg GSH
Study: 28431278
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo (saline)
Study: 25251411
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gel applied to one-half of the sockets
Study: 25251411
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no chlorhexidine gel)
Study: 21281463
Drug: Irinotecan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 80 mg/m2 i.v., LV 200 mg/m2, 5FU 450 mg/m2 bolus (Arm A)
Study: 21281463
Drug: Leucovorin 200
Normalized name: leucovorin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin 200 mg/m2 and 5FU 500 mg/m2 i.v. bolus (Arm B)
Study: 16733624
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of calcium daily
Study: 8155035
Drug: Pentoxifylline at
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline at 2000 mg/d
Study: 24377455
Drug: Bayberry juice
Normalized name: bilberry juice extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayberry juice (250 mL twice daily for 4 weeks)
Study: 29883974
Drug: intralipid/heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: intralipid/heparin infusion
Study: 18343810
Drug: Transvaginal aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvaginal aspiration of hydrosalpinx under antibiotics cover
Study: 31563697
Drug: Letrozole (LE)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (LE) combined with low-dose gonadotropins using the multiple-dose GnRH-antagonist protocol
Study: 31563697
Drug: Low-dose gonadotropins
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gonadotropins using the multiple-dose GnRH-antagonist protocol (Control Group A)
Study: 27037817
Drug: Dexmedetomidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine administered as short intravenous infusion of 1-2 µg/kg in 10 min
Study: 11753959
Drug: Alternating chemoradiotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemoradiotherapy (ALT) - 4 cycles of intravenous cisplatin (20 mg/m² for 5 days) and 5-fluorouracil (200 mg/m² for 5 days) alternated with three 2-week courses of radiotherapy (20 Gy per course, 2 Gy per day, 5 days per week).
Study: 8896529
Drug: DTPa vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa vaccine
Study: 3720707
Drug: Extended phenytoin
Normalized name: Extended Phenytoin Sodium Capsules
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended phenytoin sodium capsules (Dilantin Kapseals) - 3 capsules of 100 mg each (276 mg free acid)
Study: 3720707
Drug: Phenytoin oral
Normalized name: phenytoin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin oral suspension (Dilantin oral suspension) - 11 ml (275 mg)
Study: 27340358
Drug: Oral E.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E. coli Nissle therapy (2 capsules daily for one month)
Study: 27340358
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vegetarian diet and topical therapy only)
Study: 9002328
Drug: Treatment algorithm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment algorithm (including locally available foods, vitamin and mineral supplementation, selective use of antibiotics)
Study: 9449728
Drug: Limited-ventilation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited-ventilation group (peak inspiratory pressure maintained at 30 cm of water or less, tidal volume at 8 ml per kilogram or less)
Study: 2627387
Drug: IV labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV labetalol at doses of 0.25, 0.5, 0.75, or 1 mg/kg
Study: 31901229
Drug: Peri-articular injection
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-articular injection (PAI)
Study: 31901229
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection (IAI)
Study: 31254462
Drug: Prolonged capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prolonged capecitabine chemotherapy (1000 mg/m² per day for 2 weeks, repeated every 3 weeks for 8 cycles at most)
Study: 31254462
Drug: Prolonged capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prolonged capecitabine chemotherapy
Study: 31254462
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prolonged chemotherapy)
Study: 28323965
Drug: Daily recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily recombinant human GH (r-hGH) at a dose of 0.24 mg/kg/wk
Study: 21044831
Drug: SOD/gliadin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOD/gliadin supplement (500 mg/day for 12 weeks)
Study: 13342
Drug: Group discussion‐placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group discussion‐placebo control treatment (n = 4)
Study: 23471421
Drug: Centralized depression
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centralized depression care (patient preference for problem-solving treatment via telephone or Internet, pharmacotherapy, both, or neither) for 6 months (active treatment group; n = 73)
Study: 11507918
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene program (instruction on brushing, flossing, and professional tooth cleaning)
Study: 11507918
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (10 students with no oral hygiene training)
Study: 9022536
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg D‐alpha‐tocopheryl acetate plus 250 mg slow‐release ascorbic acid twice a day (n = 20)
Study: 9022536
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg D‐alpha‐tocopheryl acetate twice a day (n = 20)
Study: 9022536
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ascorbic acid twice a day (n = 21)
Study: 9022536
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg slow‐release ascorbic acid twice a day (n = 21)
Study: 9022536
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day (n = 20)
Study: 28957341
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy course
Study: 16096787
Drug: Angiotensin 1-7
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin 1-7 (A(1-7)) administered at a dose of 100 microg/kg per day for at least 10 days after chemotherapy.
Study: 16096787
Drug: Filgrastim (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (control group) administered over three cycles of chemotherapy.
Study: 12885265
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene cream 0.1% applied to face (standard application)
Study: 12885265
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene cream 0.1% applied to 15% body surface area (exaggerated application)
Study: 12885265
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene cream 0.1% applied to face (standard application) in photodamaged skin
Study: 12885265
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene cream 0.1% applied to 15% body surface area (exaggerated application) in photodamaged skin
Study: 11115436
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone (125 mg)
Study: 4024909
Drug: TTS‐scopolamine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS‐scopolamine (two patches)
Study: 4024909
Drug: Dimenhydrinate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate (100 mg)
Study: 20016142
Drug: Overall Ca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall Ca absorption
Study: 17296655
Drug: Three-times-daily (TID)
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-times-daily (TID) heparin dosing
Study: 12186604
Drug: Hydrocortisone (50-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortisone (50-micro g tablet once daily)
Study: 10452638
Drug: Rifabutin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (300 mg/d)
Study: 8267679
Drug: Bromfenac 25
Normalized name: bromfenac 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 25 mg
Study: 2357869
Drug: Bromfenac 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 10 mg and 25 mg
Study: 9690243
Drug: Bromfenac 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 5 mg
Study: 9675655
Drug: Symptomatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic drugs (control group)
Study: 30630815
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg and 75 mg on two following days)
Study: 30630815
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg BID for 5 days)
Study: 19767074
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (30mg/d for 14 days)
Study: 3538945
Drug: Ketanserin (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (after initial treatment with placebo)
Study: 3538945
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after initial treatment with ketanserin)
Study: 3538945
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in crossover treatment)
Study: 3538945
Drug: Ketanserin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (in crossover treatment)
Study: 24337154
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion (48 h, 30 ml/h)
Study: 15860854
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) IV every 3 weeks (AC)
Study: 10190766
Drug: Ferrous-glycine-sulfate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous-glycine-sulfate (200 mg elemental iron daily)
Study: 2085987
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (FT, 3 g)
Study: 2085988
Drug: Cotrimoxazole (CTX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (CTX, 960 mg, 3 times daily)
Study: 479908
Drug: Combined histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined histamine H1 and H2 antagonist treatment
Study: 9491827
Drug: Loratadine-pseudoephedrine (L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine-pseudoephedrine (L + PS)
Study: 6099707
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous cyclophosphamide
Study: 17091024
Drug: Sequential estradiol‐norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential estradiol‐norethisterone acetate regimen for 3 months
Study: 16770976
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) injections plus standard clinical care
Study: 11480653
Drug: Titratable oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titratable oral appliance in mandibular position MAX67
Study: 11480653
Drug: Titratable oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titratable oral appliance in mandibular position MAX
Study: 11480653
Drug: Titratable oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titratable oral appliance in mandibular position RP
Study: 9428829
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate (400 mg/day for 14 days followed by 76 days of elemental calcium 500 mg/day)
Study: 18698246
Drug: Methyl aminolevulinate
Normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl aminolevulinate (MAL) photodynamic therapy
Study: 18698246
Drug: Control (lesion-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (lesion-specific treatment, 83% cryotherapy)
Study: 12075764
Drug: Oral, killed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, killed enterotoxigenic Escherichia coli plus cholera toxin B-subunit vaccine
Study: 9524014
Drug: cilazapril 2
Normalized name: cilazapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril 2 x 2.5 mg
Study: 200357
Drug: Involved-field irradiation
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved-field irradiation and further chemotherapy
Study: 15383183
Drug: Quetiapine (300.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (300.5 mg/day mean dose, maximum 686.0 mg/day)
Study: 9012298
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) infusion at 1.5 micrograms/kg/min
Study: 17949799
Drug: i.v. pegylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. pegylated liposomal doxorubicin (PLD) (30 mg/m2) plus i.v. carboplatin (AUC=5 mg/mL min) once every 4 weeks
Study: 17949799
Drug: i.v. carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. carboplatin alone (AUC=5 mg/mL min) once every 4 weeks
Study: 8794442
Drug: E2-DG (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2-DG (1.5 mg E2 for 24 days with 0.15 mg DG for the last 12 days followed by 1 placebo tablet for 4 days)
Study: 3080291
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including antacid use)
Study: 23018440
Drug: Drug conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug conservation group
Study: 23018440
Drug: Drug conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug conservation participants on fully suppressive ART
Study: 16679825
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Lycopene (6 mg/day), Beta-carotene (4.8 mg/day), Alpha-tocopherol (10 mg/day), Selenium (75 microg/day)
Study: 18297254
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 mg)
Study: 11200748
Drug: BAL fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL fluid from s.B in sarcoidosis patients (2.64 pg/ml)
Study: 8825532
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam given two hours preoperatively
Study: 8825532
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam given immediately before induction of anaesthesia
Study: 1451729
Drug: Quinidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (50 mg orally)
Study: 6371535
Drug: Dipyridamole (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (225 mg per day) and Aspirin (975 mg per day)
Study: 30254135
Drug: Rifaximin 400
Normalized name: Rifaximin 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 400 mg three times a day for 2 weeks, then 200 mg three times a day for a further 2 weeks
Study: 21232664
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel for 6 months
Study: 21232664
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAT) - aspirin, clopidogrel, and cilostazol at discharge
Study: 21232664
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel at discharge
Study: 21232664
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAT) - aspirin, clopidogrel, and cilostazol at 6 months
Study: 21232664
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel at 6 months
Study: 19235536
Drug: Symptomatic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapies
Study: 17028293
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (300 U/kg), administered three times weekly starting 10 to 14 days before and continuing throughout radiotherapy.
Study: 17028293
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered under double-blind conditions.
Study: 31630117
Drug: Programmed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed treatment group (3 mg/kg IFX until week 6, then dose adjusted based on baseline TNF-α levels until week 54)
Study: 27469171
Drug: Taper-integrated screwed-in
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper-integrated screwed-in (TIS) implants
Study: 27469171
Drug: Both TIF
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both TIF and TIS implants
Study: 8996712
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) plus buspirone
Study: 8996712
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) plus placebo
Study: 8241011
Drug: Metoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (15 mg as a bolus intravenously, followed by an infusion of 0.04 mg/kg/hr)
Study: 3310369
Drug: Phenylpropanolamine (PPA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine (PPA), 50 mg twice daily
Study: 23525499
Drug: rIPC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIPC with disulfiram (600 mg od)
Study: 12712486
Drug: aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aprepitant 125 mg on Day 1 and 80 mg on Days 2-5
Study: 12712486
Drug: aprepitant 40
Normalized name: aprepitant 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aprepitant 40 mg on Day 1 and 25 mg on Days 2-5
Study: 12712486
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy (intravenous ondansetron plus oral dexamethasone)
Study: 1349294
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose infusion
Study: 8158512
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Oral hygiene instructions with scaling and root planing
Study: 8158512
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Oral hygiene instructions without subgingival scaling and root planing
Study: 16793562
Drug: Niacin extended-release/lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin extended-release/lovastatin (500/20 mg) once daily
Study: 16793562
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg) once daily
Study: 2179366
Drug: Long-term continuous
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term continuous subcutaneous infusion of large doses of salbutamol (greater than 14 mg/day)
Study: 6986067
Drug: Cefadroxil 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 2,000 mg once daily
Study: 4016827
Drug: Cefadroxil 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 1,000 mg once daily
Study: 6986067
Drug: Cefadroxil 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 1,000 mg twice daily
Study: 30597803
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg L-1 flumequine (FLU)
Study: 26255764
Drug: 6 weekly
Normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weekly fractions (fx/w) of radiotherapy